Alector to Participate in Upcoming Healthcare Conferences

Rhea-AI Summary

Alector, a clinical-stage biotechnology firm focused on immuno-neurology, announced its participation in two investor conferences. Firstly, at the Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, where management will be part of a panel at 10:30 a.m. ET. Secondly, they will engage in a fireside chat during the Stifel 2023 CNS Days virtually on March 28, 2023, at 12:00 p.m. ET. Webcasts for both events will be available on Alector's website, with replays accessible for 30 and 90 days respectively.

Alector is dedicated to developing therapies for neurodegenerative diseases, targeting immune dysfunction linked to conditions like Alzheimer’s and frontotemporal dementia.

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

• Cowen 43^rd Annual Health Care Conference (Boston, Massachusetts)
  • Tuesday, March 7, 2023, at 10:30 a.m. ET, panel
• Stifel 2023 CNS Days (Virtual)
  • Tuesday, March 28, 2023, at 12:00 p.m. ET, fireside chat

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the Cowen and Stifel webcasts will be available on the Alector website for 30 and 90 days, respectively, following the presentation dates.

About Alector

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com 

1AB (media)
Dan Budwick
973-271-6085 
dan@1abmedia.com

Argot Partners (investors)
Carrie McKim
Argot Partners
212.600.1902
alector@argotpartners.com

FAQ

When is Alector participating in the Cowen 43rd Annual Health Care Conference?

Alector will participate in the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 10:30 a.m. ET.

What is the date of Alector's fireside chat at the Stifel 2023 CNS Days?

The fireside chat at the Stifel 2023 CNS Days will take place on March 28, 2023, at 12:00 p.m. ET.

Where can I watch the presentations from Alector's investor conferences?

Presentations from Alector's conferences will be available on the 'Events & Presentations' page of their website.

What diseases does Alector focus on in its immuno-neurology approach?

Alector targets neurodegenerative diseases such as Alzheimer’s disease and frontotemporal dementia.

What is the focus of Alector's immuno-neurology product candidates?

Alector's product candidates focus on repairing immune dysfunction in the brain linked to degenerative disorders.